Literature DB >> 2205310

Stage-dependent effect of deferoxamine on growth of Plasmodium falciparum in vitro.

S Whitehead1, T E Peto.   

Abstract

Deferoxamine (DF) has antimalarial activity that can be demonstrated in vitro and in vivo. This study is designed to examine the speed of onset and stage dependency of growth inhibition by DF and to determine whether its antimalarial activity is cytostatic or cytocidal. Growth inhibition was assessed by suppression of hypoxanthine incorporation and differences in morphologic appearance between treated and control parasites. Using synchronized in vitro cultures of Plasmodium falciparum, growth inhibition by DF was detected within a single parasite cycle. Ring and nonpigmented trophozoite stages were sensitive to the inhibitory effect of DF but cytostatic antimalarial activity was suggested by evidence of parasite recovery in later cycles. However, profound growth inhibition, with no evidence of subsequent recovery, occurred when pigmented trophozoites and early schizonts were exposed to DF. At this stage in parasite development, the activity of DF was cytocidal and furthermore, the critical period of exposure may be as short as 6 hours. These observations suggest that iron chelators may have a role in the treatment of clinical malaria.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2205310

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  In vitro activities of novel catecholate siderophores against Plasmodium falciparum.

Authors:  B Pradines; F Ramiandrasoa; L K Basco; L Bricard; G Kunesch; J Le Bras
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

2.  Effects of synthetic siderophores on proliferation of Plasmodium falciparum in infected human erythrocytes.

Authors:  Andrea Rotheneder; Gernot Fritsche; Lothar Heinisch; Ute Möllmann; Susanne Heggemann; Clara Larcher; Günter Weiss
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

3.  Antimalarial action of hydroxamate-based iron chelators and potentiation of desferrioxamine action by reversed siderophores.

Authors:  J Golenser; A Tsafack; Y Amichai; J Libman; A Shanzer; Z I Cabantchik
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

4.  The antimalarial action of desferal involves a direct access route to erythrocytic (Plasmodium falciparum) parasites.

Authors:  M Loyevsky; S D Lytton; B Mester; J Libman; A Shanzer; Z I Cabantchik
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

5.  Stage-dependent effects of analogs of gramicidin A on the growth of Plasmodium falciparum in vitro.

Authors:  M A Otten-Kuipers; B Roelofsen; J A Op den Kamp
Journal:  Parasitol Res       Date:  1995       Impact factor: 2.289

6.  Iron chelators as therapeutic agents against Pneumocystis carinii.

Authors:  G A Weinberg
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

7.  Effects of zinc-desferrioxamine on Plasmodium falciparum in culture.

Authors:  M Chevion; L Chuang; J Golenser
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

8.  Bioactivities and Mode of Actions of Dibutyl Phthalates and Nocardamine from Streptomyces sp. H11809.

Authors:  Fauze Mahmud; Ngit Shin Lai; Siew Eng How; Jualang Azlan Gansau; Khairul Mohd Fadzli Mustaffa; Chiuan Herng Leow; Hasnah Osman; Hasidah Mohd Sidek; Noor Embi; Ping-Chin Lee
Journal:  Molecules       Date:  2022-03-31       Impact factor: 4.411

Review 9.  Transporter-Mediated Solutes Uptake as Drug Target in Plasmodium falciparum.

Authors:  Júlio César Monteiro Júnior; Arne Krüger; Giuseppe Palmisano; Carsten Wrenger
Journal:  Front Pharmacol       Date:  2022-02-07       Impact factor: 5.810

Review 10.  Influence of host iron status on Plasmodium falciparum infection.

Authors:  Martha A Clark; Morgan M Goheen; Carla Cerami
Journal:  Front Pharmacol       Date:  2014-05-06       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.